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Delivering prostate stereo-
tactic ablative radiation
therapy (SABR) with simul-
taneous boosts to dominant
intraprostatic lesions (DILs)
is technically feasible and
increases tumor control
probability. Boosting DILs
increases rectal normal tissue
complication probability,
although high levels of rectal
normal tissue complication
probability can be reduced
by minimizing maximum
rectal doses. If the a/b ratio
for prostate cancer is 1.5 Gy
or less, then high tumor
control probability and low
normal tissue complication
probability can be achievedReprint requests to: Dr Ann Henry, St. Jam
Beckett St, Leeds, LS9 7TF UK. Tel: 44 11
Henry@leedsth.nhs.uk, amhenry@doctors.net.u
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0360-3016  2014 The Authors. Published by 
http://dx.doi.org/10.1016/j.ijrobp.2014.01.042Purpose: To investigate boosting dominant intraprostatic lesions (DILs) in the context
of stereotactic ablative radiation therapy (SABR) and to examine the impact on tumor
control probability (TCP) and normal tissue complication probability (NTCP).
Methods and Materials: Ten prostate datasets were selected. DILs were defined using
T2-weighted, dynamic contrast-enhanced and diffusion-weighted magnetic resonance
imaging. Four plans were produced for each dataset: (1) no boost to DILs; (2) boost to
DILs, no seminal vesicles in prescription; (3) boost to DILs, proximal seminal vesicles
(proxSV) prescribed intermediate dose; and (4) boost to DILs, proxSV prescribed
higher dose. The prostate planning target volume (PTV) prescription was 42.7 Gy
in 7 fractions. DILs were initially prescribed 115% of the PTVProstate prescription,
and PTVDIL prescriptions were increased in 5% increments until organ-at-risk con-
straints were reached. TCP and NTCP calculations used the LQ-Poisson Marsden,
and Lyman-Kutcher-Burman models respectively.
Results: When treating the prostate alone, the median PTVDIL prescription was 125%
(range: 110%-140%) of the PTVProstate prescription. Median PTVDIL D50% was
55.1 Gy (range: 49.6-62.6 Gy). The same PTVDIL prescriptions and similar PTVDIL
median doses were possible when including the proxSV within the prescription.
TCP depended on prostate a/b ratio and was highest with an a/b ratio Z 1.5 Gy,
where the additional TCP benefit of DIL boosting was least. Rectal NTCP increased
with DIL boosting and was considered unacceptably high in 5 cases, which, when re-
planned with an emphasis on reducing maximum dose to 0.5 cm3 of rectumes’s Institute of Oncology,
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whole prostate without DIL
boosting.(Dmax0.5cc), as well as meeting existing constraints, resulted in considerable rectal
NTCP reductions.
Conclusions: Boosting DILs in the context of SABR is technically feasible but should
be approached with caution. If this therapy is adopted, strict rectal constraints are
required including Dmax0.5cc. If the a/b ratio of prostate cancer is 1.5 Gy or less, then
high TCP and low NTCP can be achieved by prescribing SABR to the whole prostate,
without the need for DIL boosting.  2014 The Authors. Published by Elsevier Inc.
All rights reserved.Introduction
External beam radiation therapy (EBRT) in prostate cancer
(PCa) traditionally considers thewhole prostate as the clinical
target volume (CTV), without gross tumor volume (GTV)
definition.Modern imaging allows identification of dominant
intraprostatic lesions (DILs) (1). These are frequently the
source of local failure and can be considered GTVs (2-4).
Increased radiation doses in PCa result in increased
biochemical control (5), but dose escalation to the whole
prostate is limited by the tolerance of surrounding normal
tissues. An alternative strategy could irradiate the whole
prostate but simultaneously escalate dose to the DILs (3).
The literature concerning simultaneous EBRTDIL boosts
uses conventional fractionation or moderate hypofractiona-
tion to treat the prostate and DILs (3,6-13). Stereotactic
ablative radiation therapy (SABR) uses ultra-
hypofractionation to deliver escalated doses in a small
number of treatments. Theoretically, this is radiobiologically
advantageous: PCa may have a low a/b ratio (w1.5 Gy) and
thus should be sensitive to high doses per fraction (14).
This study investigates boosting DILs using volumetric
modulated arc therapy (VMAT) within the context of
SABR: a SABR dose was prescribed to the prostate with a
simultaneous DIL SABR boost. The impact on tumor
control probability (TCP) and normal tissue complication
probability (NTCP) was examined.
Methods and Materials
Imaging and contouring
Ten prostate datasets were selected (the first patients in a pilot
study investigating DIL boosting in the context of high-dose-
rate [HDR] brachytherapy). Clinical characteristics are
shown in Supplementary Table E1. Patients underwent mul-
tiparametric magnetic resonance imaging (MRI) and plan-
ning computed tomography (CT) scans within a period of a
few hours. MRI datasets were acquired with an Avanto
(Siemens AG, Munich, Germany) 1.5-T scanner using
phased-array pelvic coils and consisted of T2-weightedMRI,
diffusion-weighted (DW) MRI, and dynamic contrast-
enhanced (DCE) MRI. For DW MRI, apparent diffusion
coefficientmapswere generated from a single-shot spin echo-
echo planar imaging sequence with b values of 0, 150, and
500 s/mm2. For DCEMRI, volume transfer constant (Ktrans)maps were generated by fitting a Tofts (15) 1-compartment
model to concentration-time data for 200 acquisitions with
temporal resolution 2 s, acquired using a 3-dimensional (3D)
spoiled gradient echo sequence, with a bolus injection of
0.1 mmol/kg gadoteric acid (Dotarem; Guerbet Group, Vil-
lepinte, France) administered at 3 mL/s after 10 s and a
patient-specific arterial input function measured in the iliac
artery. An experienced radiologist delineated DILs on the
MRI sequences based on low-intensity on T2-weightedMRI,
low apparent diffusion coefficient map values, and high
Ktransmap values, togetherwith the prostate and urethra. The
CTVDIL was the combined DIL volume from each MRI
sequence (Fig. 1) expanded 4 mm to the PTVDIL.
Images were coregistered with the planning CT by using
automatic soft tissue matching (nondeformable) with
manual alteration if necessary, paying particular attention
to the prostate-rectal interface and regions containing DILs.
Patients received enemas and were instructed to have full
bladders. The rectum, bladder, and femoral heads were
contoured as organs-at-risk. The urethra was expanded
w1.5 mm circumferentially to create a urethral planning
organ at risk volume (PRV), with a diameter of 5 to 6 mm.
The CTVProstate was the prostate alone, expanded 6 mm
to PTVProstate. The proximal 1 cm of seminal vesicles (SV)
was included in a separate CTV: CTVProstateþSV, expanded
6 mm to PTVProstateþSV.Prescription and coverage
The PTVProstate prescription was 42.7 Gy in 7 fractions
(intended for delivery on alternate week days over 15 days:
Monday, Wednesday, Friday, Monday, Wednesday, Friday,
and Monday). Coverage requirements are shown in Table 1.
Plans initially prescribed 42.7 Gy to the prostate without DIL
boosts. Planswere then createdwith simultaneousDILboosts:
the PTVDIL prescription was increased in 5% increments
starting at 115% of the PTVProstate prescription until organ-at-
risk or conformity constraintswere reached. If a boost of 115%
was not achievable, the PTVDIL prescription was reduced in
5% increments until the plan became acceptable.
Plans were then created that delivered the highest
achievable PTVDIL prescription to DILs, 42.7 Gy to the
prostate, and that also included the proximal SV (proxSV)
within PTVProstate þ SV, initially prescribed 32.4 Gy in 7
fractions (equivalent dose in 2 Gy fractions [EQD2]1.5 Gy:
56.7 Gy), a microscopic tumoricidal dose, and then 36.5 Gy
Fig. 1. DIL defined on T2-weighted (a), diffusion-weighted (b), and dynamic contrast-enhanced MRI (c); combined DIL
volume (CTVDIL) (d); a plan without DIL boost (e) and a plan with PTVDIL boost of 125% (f).
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may improve tumor control.
The prescription doses for both the prostate and DIL
PTVs were such that at least 95% of the structure received
at least 95% of the prescription dose (ie, D95%  95% of
prescription dose). To allow gradients for DIL boosting and
to maximize PTVDIL doses, there were no limits on dose
heterogeneity.
Organs-at-risk
Constraints are shown in Table 1.
Plans
Four plans were produced for each dataset, as follows: (1)
plan set A: no DIL boost delivery, no SV in prescription; (2)plan set B: boost to DILs, no SV in prescription; (3) plan set
C: boost to DILs, proxSV prescribed intermediate dose; and
(4) plan set D: boost to DILs, proxSV prescribed higher
dose.
Planning
Monaco version 3.3 (Elekta AB, Sweden) was used with a
Monte Carlo algorithm and the Agility multileaf collimator
with 5-mm leaves (Elekta AB, Sweden). VMAT was
planned with 1 anterior 270 arc (225/135) for 9 pa-
tients, and 3 partial arcs (290/70, 180/240,
120/180) for 1 patient who had a bilateral hip pros-
theses. The final plan in each set was calculated using a 2-
mm grid. There were 150 control points per arc. Normal
tissues took priority over target coverage. Prioritizing in-
dividual organs-at-risk is not required in Monaco.
Table 1 Coverage requirements and organ-at-risk constraints
Volume Requirement/constraint Source/explanation
CTVProstate Minimum dose Z 40.6 Gy (95%) HYPO-PC-RT phase 3 trial, 42.7 Gy in
7# arm (29)
PTVProstate Volume receiving 40.6 Gy (V95%)
95%/Dose to 95% (D95%)
40.6 Gy (95%)
HYPO-PC-RT phase 3 trial, 42.7 Gy in
7# arm (29)
PTVProstate Dose to 99% (D99%) 38.4 Gy (90%) HYPO-PC-RT phase 3 trial, 42.7 Gy in
7# arm (29)
PTVDIL Volume receiving 95% of prescribed
dose 95%/Dose to 95% (D95%)
95% of prescribed dose
PTVProstateþSV minus PTVProstate Volume receiving 95% of prescribed
dose (V95%) 95%
Applicable when including proximal
SV within prescription
Conformity index 1.2 Volume of 95% isodose/PTV volume
To limit high dose spill (34)
R50 5.5 Volume of 50% isodose/PTV volume
To limit intermediate dose spill (34)
Maximum dose at 2 cm from PTV 29.9 Gy (70%) To limit intermediate dose spill
Minor deviation to 34.2 Gy (80%)
permitted if all other constraints met
Rectum (rectosigmoid junction to anus) V41.4 Gy (97%) <3% Biologically equivalent for 7# regimen
to 74 Gy in 37# arm of phase 3
CHHiP trial (35)
V38.4 Gy (90%) <15% HYPO-PC-RT phase 3 trial, 42.7 Gy in
7# arm (29)
V32.0 Gy (75%) 35% HYPO-PC-RT phase 3 trial, 42.7 Gy in
7# arm (29)
V28.0 Gy (65%) 45% HYPO-PC-RT phase 3 trial, 42.7 Gy in
7# arm (29)
V24.8 Gy (58%) <70% Biologically equivalent for 7# regimen
to 74 Gy in 37# arm of phase 3
CHHiP trial (35)
V19.6 Gy (46%) <80% Biologically equivalent for 7# regimen
to 74 Gy in 37# arm of phase 3
CHHiP trial (35)
Bladder V41.4 Gy (97%) <5%*
V34.7 Gy (81%) <25%
V29.9 Gy (70%) <50%
All biologically equivalent for 7#
regimen to 74 Gy in 37# arm of
phase 3 CHHiP trial (35)
Femoral heads Dmax 29.9 Gy (70%) HYPO-PC-RT phase 3 trial, 42.7 Gy in
7# arm (29)
V29.9 Gy (70%) <50% Biologically equivalent for 7# regimen
to 74 Gy in 37# arm of phase 3
CHHiP trial (35)
Urethra Dmax <58.1 Gy
D10% <53.3 Gy
D50% <50.7 Gy
Biologically equivalent for 7# regimen
to 38 Gy in 4# arm of phase 3 PACE
trial (based on high-dose-rate
brachytherapy monotherapy
constraints) (36)
Abbreviations: CHHiP Z Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer; HYPO-PC-
RT Z HYPOfractionated radiotherapy of intermediate risk localised prostate cancer: a phase 3, randomised, open, multicentre trial;
CTVProstate Z Prostate Clinical Target Volume; PACE Z Prostate Advances in Comparative Evidence; PTVDIL Z Dominant intra-prostatic lesion
Planning Target Volume; PTVProstateZ Prostate Planning Target Volume; PTVProstate þ SVZ Prostate þ Seminal Vesicle Planning Target Volume; #Z
fraction; * V41.4Gy relaxed to <9% in two cases with median lobe hypertrophy and small bladder volumes which meant prescription of prostate dose
without DIL boost not possible if maintaining V41.4Gy<5%.
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TCP was calculated using the LQ-Poisson Marsden model,
originally described by Nahum and Sanchez-Nieto (16),
and discussed in the Supplementary Material.
Three sets of parameters were used for TCP calculation,
each representing a different a/b ratio: 10 Gy, 3 Gy, and
1.5 Gy (Table 2) (17). Clonogen density in the DIL region
was assumed to be 1  107 cm3. Using an approach
similar to that reported by Nutting et al (9), we assumed the
ratio of clonogens in DIL (s) to clonogens in the non-DIL
prostate was 90:10. Clonogen density in the non-DIL
prostate was therefore:
rZ
1  107 median_total_DIL_volume_ per_ prostate  10
90
median_

prostateDIL_volume
TCP was calculated using dose-volume histograms
(DVH) for the CTVDIL and the non-DIL prostate [ie,
(CTVProstate)  (CTVDIL(s))].
NTCP for the rectum, bladder, and femoral heads was
calculated using the Lyman-Kutcher-Burman model (18,19)
with Niemierko’s equivalent uniform dose (20), as described
in Supplementary Material. QUANTEC [Quantitative Ana-
lyses of Normal Tissue Effects in the Clinic] parameters for
grade 2 þ rectal toxicity or bleeding were adopted for prin-
cipal rectal NTCP evaluation (21). For further exploration,
parameters for severe rectal bleeding and frequency, anal
incontinence, and parameters considering the impact of
previous abdominal surgery were employed (22). The choice
of modeling parameters is discussed in Supplementary
Materials. Parameters are shown in Table 3.
To assess the sensitivity of TCP calculations to small
alterations in input parameters, a sensitivity analysis was
performed, as described in Supplementary Material. Cal-
culations were performed using Biosuite software (devel-
oped at Clatterbridge Cancer Centre, UK) (17) using
differential DVHs with 0.1 Gy bin width.
Statistics
The Wilcoxon signed-rank exact test was used to compare
plan parameters, TCP and NTCP as these were non normallyTable 2 TCP parameters (17)
a
d
(Gy1) sa ( Gy
1) a
High a/b
Prostate minus DIL (s) 0.301 0.114
DIL 0.301 0.114
Low a/b
Prostate minus DIL (s) 0.217 0.082
DIL 0.217 0.082
Very low a/b
Prostate minus DIL (s) 0.155 0.058
DIL 0.155 0.058
Abbreviations: DIL Z dominant intraprostatic lesion; TCP Z tumor controdistributed. Median values and ranges are therefore pre-
sented. The following were compared: plan set B was
compared to plan set A, plan set C to plan set B, and plan setD
to plan set C. Linear correlations were examined using the
Pearson correlation coefficient (r). SPSS, version 19, soft-
ware was used. Tests were 2-tailed. A P value of <.05 was
significant.Results
A total of 17 PTVDILs were defined (1, 2, and 3 DILs in 5,
3, and 2 cases respectively). Median PTVDIL volume was
3.4 cm3 (range: 1.5-51.6 cm3). Median PTVProstate volume
was 61.8 cm3 (range: 38.9-128.5 cm3).
When the prostate was treated alone (ie, without proxSV
inclusion) and prescribed the highest feasible boost to DILs
(plan set B), the median PTVDIL prescription achieved was
125% of the PTVProstate prescription (53.4 Gy in 7 fractions,
EQD21.5 Gy: 139.3 Gy) and ranged from 110% (EQD21.5 Gy:
110.3 Gy) to 140% (EQD21.5 Gy: 171.6 Gy). The median
D50% received by a PTVDIL was 55.1 Gy (EQD21.5 Gy:
147.5 Gy); range: 49.6 Gy (EQD21.5 Gy: 121.7 Gy) to 62.6 Gy
(EQD21.5 Gy: 186.8 Gy). Unsurprisingly, delivering boosts to
PTVDILs compared to not delivering boosts, resulted in sig-
nificant increases in PTVDILD50%. This was accompanied by
increases in monitor units and estimated delivery times
(Table 4).
During planning, the rectum was most frequently the
dose-limiting structure. For all boost plans (plan sets B, C,
and D), linear correlations were observed between the
PTVDIL prescription achieved and the minimum distance of
a PTVDIL from the rectum (rZ0.56, PZ.019) and the vol-
ume of PTVDIL overlapping with the rectum (rZ0.66,
PZ.004). In addition, PTVDIL D50% correlated with the
volume of PTV_DIL overlapping with the rectum (plan sets
B, C and D: rZ0.69, 0.58, 0.62; PZ.002, PZ.016,
PZ.008, respectively) and, in plan sets B and D, with the
minimum distance of PTVDIL from the rectum (plan set B:
rZ0.62, PZ.008, plan set D: rZ0.50, PZ.045). No sig-
nificant correlations were observed between PTVDIL mini-
mum distance from, or volume of overlap with, the urethra or
bladder and the PTVDIL prescription or D50%. There was no/b (Gy) rclon (cm
3) Td (days) Tk (days)
10 6.2∙104 0 45
10 1.0∙107 0 45
3 6.2∙104 0 45
3 1.0∙107 0 45
1.5 6.2∙104 0 45
1.5 1.0∙107 0 45
l probability.
Table 3 NTCP parameters
Organ End point TD50 (Gy) m n Source
Principal rectal NTCP evaluation
Rectum Grade 2þ late toxicity or rectal bleeding 76.9 0.13 0.09 Michalski et al (21)
Supplementary anorectal NTCP evaluation
Rectum Severe rectal bleedingy- all patients 81 0.14 0.13 Peeters et al (22)
Rectum Severe rectal bleedingy- patients without
history of abdominal surgery
85 0.14 0.11 Peeters et al (22)
Rectum Severe rectal bleedingy- patients with
history of abdominal surgery
78 0.14 0.11 Peeters et al (22)
Rectum Severe frequencyz- all patients 84 0.24 0.39 Peeters et al (22)
Anus* Severe anal incontinencex, all patients 105 0.43 1 Peeters et al (22)
Anus* Severe anal incontinencex, patients without
history of abdominal surgery
157 0.45 1 Peeters et al (22)
Anus* Severe anal incontinencex, patients with
history of abdominal surgery
74 0.45 1 Peeters et al (22)
Bladder Contracture/volume loss 80 0.11 0.5 Burman et al (37)
Femoral heads Necrosis 65 0.12 0.25 Burman et al (37)
Abbreviations: mZ dose-response parameter; nZvolume effect parameter; NTCPZ normal tissue complication probability; TD50Z Dose resulting
in 50% probability of complication in a uniformly irradiated tissue.
* Anus was defined as the most caudal 3 cm of the rectal structure.
y Defined as bleeding that requires transfusion or laser treatment.
z Defined as stool frequency of 6 or greater times per day.
x Defined as loss of mucous, stools or blood necessitating the use of pads at least twice per week.
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tion or PTVDIL D50%.
For smaller volume PTVProstates, respecting conformity
index (CI) constraints was an additional dose-limiting
factor; and for larger volume PTVs, respecting the
maximum dose 2 cm from the PTVProstate (Dmax2 cm) was
also dose limiting.
When the proxSV were included in the prescription,
prescribed 32.4 Gy (plan set C) or 36.5 Gy (plan set D), it
was possible to deliver the same PTVDIL prescription as
when DILs were boosted without proxSV inclusion.
Furthermore, there were no significant differences in
PTVDIL D50% (Table 4). Plans prescribing 32.4 Gy to the
proxSV (plan set C) compared to plans delivering DIL
boosts but without proxSV prescription (plan set B) resul-
ted in significant increases in CI, R50 (volume of 50%
isodose/volume of PTV), and Dmax2cm. Similarly, pre-
scribing 36.5 Gy (plan set D) to proxSV, compared to
32.4 Gy (plan set C), resulted in increases in CI, R50, and
Dmax2cm (Table 4).
TCP for DILs and the non-DIL prostate varied
depending on the a/b ratio and accompanying parameters
used (Table 5). For all a/b ratios, boosting DILs resulted in
significant increases in TCP in DILs and non-DIL prostates.
The higher the a/b ratio, the greater the benefit of boosting
DILs, with gains in median TCP of 14% (from 76.5%-
90.5%) when boosting for an a/b ratio of 10 Gy compared
to 6.7% (90.3%-97.0%) for an a/b ratio of 3 and 4.4%
(94.4%-98.8%) for an a/b ratio of 1.5 Gy. There were no
differences in TCP when the proxSV were included within
the prescription. With a/b ratio of 1.5 Gy in nonboost plans
(plan set A), TCP for DILs and for the remaining prostate
exceeded 90% and 95%, respectively, in 9 of 10 cases.TCP sensitivity analysis results are shown in
Supplementary Table E2. Small changes in TCP input pa-
rameters have the greatest impact with an a/b ratio of
w10 Gy and least impact with an a/b ratio of w1.5 Gy.
NTCP for grade 2þ late rectal complications (QUAN-
TEC parameters) was consistently low (<3.5%) when
prescribing SABR to the whole prostate, without DIL
boosting (plan set A; Table 5). There was a significant in-
crease in rectal NTCP when delivering DIL boosts. Pre-
scribing to the proxSV did not increase rectal NTCP
further. Rectal NTCP was <15% in 35 of 40 plans. A
strong linear correlation was noted between maximum dose
received by 0.5 cm3 (Dmax0.5cc) of rectum and rectal NTCP
in all boost plans (ie, plan sets B, C, and D; r: 0.88, 0.97,
and 0.95 respectively; all P.001) (see Supplementary
Fig. E1). Rectal NTCP did not exceed 5% and 15% in
cases where rectal Dmax0.5cc did not exceed 44.1 Gy and
47.1 Gy, respectively. There was no correlation between
rectal NTCP and PTVDIL prescription or D50%, except in
plan set C, where a moderate correlation was observed
between rectal NTCP and D50% (rZ0.488, PZ.047).
Of the 5 “worst” rectal NTCP plans (using QUANTEC
parameters), 3 came from 1 dataset containing 2 DILs, the
larger abutting the rectum, both boosted to 130%. The 2 other
worst plans came from 1 dataset containing a large PTVDIL
(51.6 cm3) prescribed 125%, which overlapped with the
rectum.All 5 cases were replannedwith the aim of delivering
the same PTVDIL prescription while respecting the existing
constraints (Table 1) and also reducing rectal Dmax0.5cc to
<47.1 Gy. In 4 cases the same PTVDIL prescription level was
achieved, albeit with lower PTVDILD50%.Rectal NTCPwas
reduced considerably (from 30.8%, 47.1%, 31.9%, and
22.6% to 1.7%, 3.4%, 2.5%, and 8.9%), accompanied by
Table 4 Plan parameters
Volume treated
P Value where
significant (Plan set B
compared
with Plan set A,
Plan set C compared with
Plan set B, and Plan
set D compared
with Plan set C)
Plan set A: no
boost to DILs,
prostate alone
(nZ10)
Plan set B: Boost to
DILs, prostate
alone (nZ10)
Plan set C: Boost to
DILs, proximal
seminal vesicles
treated to
intermediate dose
(nZ10)
Plan set D: Boost to
DILs, proximal
seminal vesicles
treated to high dose
(nZ10)
Median Range Median Range Median Range Median Range
Highest achievable
PTVDIL prescription (% of
PTVProstate
prescription)
NA NA 125 110-140 125 110-140 125 110-140 Identical
Median dose to
PTVDIL
(D50%; Gy)
43.8 43.4-45.3 55.1* 49.6-62.6 54.9 50.1-62.5 55.3 49.5-61.8 *Plan set B > A: P<.001
Conformity index 1.05 1.00-1.12 1.06 1.02-1.11 1.13y 1.09-1.17 1.16z 1.12-1.20 yPlan set C > B: PZ.004
zPlan set D > C PZ.004
R50 3.55 3.31-4.05 3.57 3.34-4.14 4.16y 3.97-4.73 4.32z 4.06-4.94 yPlan set C > B: PZ.002
zPlan set D > C: PZ.004
Maximum dose at 2 cm
from PTV
26.1 23.2-31.0 27.4 25.5-32.7 29.0y 26.8-33.4 29.8z 27.2-33.2 yPlan set C > B: PZ.002
zPlan set D > C: PZ.049
Monitor units per fraction 1980 1655-2654 2313* 2117-2562 2314 1948-2618 2372 2099-2773 *Plan set B > A: PZ.027
Estimated delivery time
(seconds)
209 173-314 253* 230-353 248 211-343 260 229-312 *Plan set B > A: PZ.01
Abbreviations are as in Tables 1 and 2.
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case, it was not possible to maintain coverage, to respect
constraints, and to lower rectal dose, so PTVDIL prescription
was lowered by 5% to 120%,which resulted in reduced rectal
NTCP (31% to 5.6%). Thus, rectal NTCP became <15% in
all cases.
Anorectal NTCP based on alternative parameters was
generally acceptable. Results are presented in Supplementary
Table E4 and discussed in Supplementary Materials.Discussion
This study investigated boosting DILs while maintaining
organ-at-risk constraints in the context of SABR. DIL dose
escalation to a median of 125% of the PTVProstate pre-
scription (EQD21.5: 139 Gy) is feasible. This resulted in
increased TCP in DILs and the non-DIL prostate, likely
because of the dose gradients required to deliver boosts.
DIL boosting also increased rectal NTCP, and, in some
cases, rectal NTCP became unacceptable.
Simultaneous EBRT DIL boosts up to 4.1 Gy and 2.7 Gy
per fraction have been delivered in planning and clinical
studies respectively, to total doses up to EQD21.5 220 Gy
and 114 Gy (3,6-13). The non-DIL prostate received up to
2.8 Gy and 2.7 Gy per fraction in planning and clinical
settings respectively (up to EQD21.5: 93.5 Gy and 81.4 Gy)
(3,6-13). Late grade 2þ rectal and bladder toxicity rates up
to 15% and 43% are reported clinically (3). We are unaware
of other publications which examined TCP and NTCP
using SABR to the whole prostate (EQD21.5: 92.7 Gy) withsimultaneous SABR DIL boosts. Previous studies have
observed the impact of DIL location on boost feasibility
(7,11). We also found that PTVDIL proximity to the rectum
and volume of rectal overlap influenced the PTVDIL pre-
scription level and PTVDIL D50%. Unlike studies using
conventional fractionation, prescribing SABR requires
limits for high- and intermediate-dose spill. These also
influenced the boosts that could be achieved.
It was possible to prescribe the same PTVDIL pre-
scriptions and achieve similar PTVDIL median doses when
including the proxSV, when prescribing both 32.4 Gy and
36.5 Gy. This potentially provides an SABR option for
intermediate-risk PCa patients at higher risk of SV inva-
sion. Including the proxSV resulted in “pulling out” of
isodoses posteriorly, reflected by increases in CI and R50.
Despite this, there was no significant increase in rectal
NTCP.
This study has limitations, and several factors must be
addressed before adopting this strategy clinically. First, the
optimal method for defining DILs is debated. Existing
studies use multiparametric MRI, MR spectroscopy, radio-
labeled indium and choline positron emission tomography.
We used multiparametric MRI, in keeping with guidelines
(1). Based on histopathological correlation with prostatec-
tomy specimens, T2-weighted sequences combined with
DW MRI sequences, or DW combined with DCE MRI
sequences, have sensitivities and specificities of 70% to
87% (23, 24). Combining all 3 sequences has been shown
to result in a receiver operator curve area under the curve
(AUC) of 0.94 (25). Second, accurate image coregistration
is essential. We used soft tissue automatch with manual
Table 5 TCP and NTCP
a/b (Gy)
Plan set A:
no boost to
DILs, prostate
alone
Plan set B:
Boost to DILs,
prostate
alone
Plan set C: Boost
to DILs, proximal
seminal vesicles
treated to
intermediate
dose
Plan set D: Boost
to DILs, proximal
seminal vesicles
treated to
high dose
P Value where significant
(Plan set B compared
with Plan set A, Plan
set C compared
with Plan set B,
and Plan
set D compared
with Plan set C)Median Range Median Range Median Range Median Range
TCP Prostate
minus DIL (s)
10 80.5 76.9-83.0 87.9* 82.2-89.9 87.7 83.9-89.0 87.2 82.6-88.5 *Plan set B >
A: PZ.002
3 92.0 90.4-93.1 95.5* 93.1-96.5 95.3 93.6-96.1 95.2 93.3-95.8 *Plan set B >
A: PZ.002
1.5 95.5 94.4-96.2 97.7* 96.3-98.4 97.5 96.5-98.1 97.4 96.4-97.9 *Plan set B >
A: PZ.002
TCP DIL (s) 10 76.5 58.6-84.0 90.5* 79.5-96.3 90.7 80.0-96.2 90.6 79.4-96.0 *Plan set B >
A: P<.001
3 90.3 81.6-93.7 97.0* 92.7-99.2 97.0 93.0-99.2 97.1 92.4-99.1 *Plan set B >
A: P<.001
1.5 94.4 89.3-96.6 98.8* 96.2-100 98.7 96.4-100 98.8 96.0-100 *Plan set B >
A: P<.001
NTCP rectum 3 2.8 1.4-3.3 11.4* 3.8-30.8 10 0.6-47.1 9.6 3.5-31.9 *Plan set B >
A: PZ.002
NTCP bladder 3 0 0 0 0 0 0 0 0
NTCP femoral
heads
3 0 0 0 0 0 0 0 0
Abbreviations: DILs Z dominant intraprostatic lesions; NTCP Z normal tissue complication probability; SD Z standard deviation; TCP Z tumor
control probability.
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prove superior, as this could deal with alterations in pros-
tate shape and discrepancies in prostate size between im-
aging modalities more adequately than we were able to
using rigid registration but this has not been validated in the
setting of DILs. The optimal method of registration might
well include models which add additional DIL margins to
specifically account for registration errors, although tech-
niques requiring additional margins may prove difficult to
implement without unacceptable increases in NTCP. Un-
certainties resulting from DIL definition and registration
will reduce the actual TCP benefit achieved from DIL
boosting to less than that calculated here. Third, the addi-
tion of catheterization at planning would facilitate reliable
identification of the urethra.
Fourth, robust image guidance together with appropriate
CTV-PTV margins are essential. We used 6-mm prostate
CTV-PTV margins, compatible with daily online fiducial-
based image guidance (without intrafraction motion
tracking) (26). There is evidence that intrafraction motion
becomes more problematic with increasing treatment time,
particularly beyond 8 min (27). Our plans had average
estimated delivery times of 4.2 minutes (maximum,
5.9 minutes). We therefore do not envision that intrafraction
motion would be a major concern. The use of flattening
filterefree (FFF) treatments would further reduce delivery
times. We replanned 5 boost plans using FFF and estimated
delivery times reduced by 116 seconds on average. Whileintensity modulated radiation therapy (rather than VMAT)
could potentially achieve similar boosts, the longer delivery
times would be more of a concern in the absence of
intrafraction motion tracking.
Fifth, the most appropriate DIL CTV-PTV margin is un-
certain. A variety of margins have previously been adopted
(0-8 mm) (3). The phase 3 Focal Lesion AblativeMicroboost
in Prostate Cancer (FLAME) trial, which prescribes 77 Gy in
35 fractions to the prostate, with or without 95 Gy simulta-
neous DIL boost, uses 4-mm DIL CTV-PTV margins (12).
We also used 4-mmmargins. The concept of aDILCTV-PTV
margin within a larger (ie, whole prostate) PTVmargin is not
consistent with the derivation ofmargins using the traditional
vanHerkmethods, which are based on the CTV receiving the
appropriate dose with a standard penumbra of 5 mm, and
doses falling from 95% at the edge of the PTV to 20% at the
edge of the penumbra (28). In the case of DILs, doses were
falling from a median of 125% to approximately 100%.
Furthermore, the dose fall-off around the DILs was relatively
shallow, such that each DILwas generally well encompassed
within the 95% isodose relevant to that DIL, thus adding
additional coverage security to that created by the 4-mm
CTV-PTV DIL margin to help account for intrafraction
motion as well as uncertainties in DIL definition and
registration.
Adequately addressing the above issues, while relevant
in the context of conventional fractionation, is even more
important in the context of SABR, where the TCP
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greater.
The optimal organ-at-risk constraints for prostate SABR
are unknown. We adopted the same constraints as a phase 3
trial, which delivers the same PTVProstate prescription dose
(29), and added additional constraints. Despite this rela-
tively conservative approach, plans which included DIL
boosts were sometimes associated with unacceptable rectal
NTCP. The “acceptable” level of grade 2þ late rectal
complications has not been defined. QUANTEC suggests
constraints for conventional 3D-conformal RT which
should result in 15% late grade 2þ rectal complications
(21). Most of our plans satisfied this limit, but 5 did not.
Strong correlations between rectal Dmax0.5cc and rectal
NTCP were demonstrated. This is not surprising as NTCP
modelling considered the rectum as a serial structure, thus
higher doses have greater impact on NTCP. Replanning the
5 “worst” cases, aiming to reduce rectal Dmax0.5cc yet still
deliver the highest possible boost, resulted in considerable
reductions in rectal NTCP, and only once was it necessary
to reduce the PTVDIL prescription to achieve this.
When considering alternative NTCP parameters for
anorectal toxicities and personalizing NTCP based on a
history of abdominal surgery, NTCP levels were generally
low. Those cases in which NTCP levels were highest, based
on alternative parameters, were those in which rectal NTCP
was unacceptable using QUANTEC parameters, and the
replans predicted acceptable NTCP levels.
The applicability of our modeling approach in the SABR
setting is uncertain (21). The TCP and NTCP models used
rely on the LQ model. There is debate about the appro-
priateness of this model at high doses per fraction, therefore
calling into question the validity of our calculations
(30,31). Two points, however, should be emphasized. First,
the concern about the validity of the LQ model begins at
fraction sizes of at least 10 Gy (30,31), while the doses in
this study were <10 Gy per fraction. Second, the concern
regarding the LQ model at high doses per fraction is that it
overestimates cell killing, thus overestimating NTCP (31).
The potential inaccuracies in our calculations can therefore
be considered “safe.” Regarding TCP, sensitivity analysis
revealed TCPs based on an a/b ratio of w1.5 Gy are most
robust to small changes in input parameters. If the “true”
TCP parameters for ultrahypofractionation are slightly
different from those adopted here and if the PCa a/b ratio is
w1.5 Gy, then these will be the most reliable TCP calcu-
lations. Long-term clinical SABR data are required before
these issues can be resolved.
The differences between DILs and the non-DIL prostate
are incompletely understood. We assumed a higher clono-
genic density in DILs than the remaining prostate and
therefore handled the DILs and non-DIL prostate separately.
If DILs are the most likely source of local failure, then TCPs
calculated for DILs are more relevant. CTVs were used for
TCP calculations instead of PTVs, thus avoiding the un-
certainties which arise as the CTV-PTV margin contains a
lower clonogenic density than that of the CTV. The a/b ratiofor PCa is debated. TCP varied with the a/b ratio adopted: a/
b Z 1.5 Gy resulted in the highest TCP, and the benefit of
boosting DILs was least in this setting. Indeed, in nonboost
plans,a/bZ 1.5Gy resulted in TCP>94%and>89% for the
non-DIL prostate and DILs, respectively. Nonboost plans
were also associatedwith low rectal NTCP, and so, if PCaa/b
isw1.5Gy, then prostate SABRwithout DIL boosting is safe
and acceptable. If the a/b ratio is higher, then TCP is more
limited, evenwithDILboosting, and further increases inTCP
would cause unacceptable increases in rectal NTCP. As
mentioned above, the uncertainties associated with DIL
definition and registration will result in the realized TCP
from boosting being less than that calculated, thus reinforc-
ing the role of SABR to the whole prostate without DIL
boosting if the a/b ratio of PCa isw1.5 Gy.
Although this planning study included some patients
with higher risk disease than we would envision treating
with this technique, our approach was justifiable as
approximately 43% of patients with low- to intermediate-
risk PCa have DILs identifiable on MRI (32). Most pa-
tients also received neoadjuvant androgen deprivation
therapy, which is used less frequently in lower risk pa-
tients. If adopted clinically, the impact of hormone ther-
apy on DIL appearance would need to be considered
where relevant (33).Conclusions
Accepting these limitations and uncertainties, it is techni-
cally feasible to create SABR VMAT plans which boost
DILs. This increases TCP. Rectal NTCP also increases and
can become unacceptable, although high levels of rectal
NTCP can be reduced by minimizing maximum rectal
doses. TCP is influenced by prostate a/b ratio. The higher
the true a/b ratio in PCa, the smaller the gap between doses
required for adequate tumor control and acceptable rectal
toxicity. Boosting DILs in the context of SABR should be
approached with caution. If adopted, strict organ-at-risk
constraints are required, including maximum rectal dose. If
PCa a/b ratio is 1.5 Gy, then for most patients, high TCP
can be achieved with low NTCP by delivering one SABR
dose to the whole prostate, without DIL boosting, and
thereby avoiding the uncertainties associated with the DIL
definition and planning process.References
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